Clinical trial · Interventional
Investigating and Characterizing the Immune Response to Prostate Cancer
NCT03331367CI-TRIAL-00046498completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is a clinical study to investigate and characterize the immune response profile to four different prostate cancer treatments (total cryotherapy, focal cryotherapy, Cyberknife SBRT, and radical prostatectomy) in patients with localized prostate cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood draw | Procedure | — | UNRESOLVED |
| Urine sample | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- ACTIVE_COMPARATOR
- label
- Total Cyrotherapy of the Prostate
- description
- Patients who will undergo total cryotherapy of the prostate will be evaluated for immune markers using a blood draw and urine sample collected at three timepoints (baseline, 2-3 weeks post cryotherapy, 3 months post cryotherapy)
- interventionNames
- Procedure: Blood draw
- Procedure: Urine sample
- type
- ACTIVE_COMPARATOR
- label
- Focal Cryotherapy of the Prostate
- description
- Patients who will undergo focal cryotherapy of the prostate will be evaluated for immune markers using a blood draw and urine sample collected at three timepoints (baseline, 2-3 weeks post cryotherapy, 3 months post cryotherapy)
- interventionNames
- Procedure: Blood draw
- Procedure: Urine sample
- type
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient is willing and able to freely sign informed consent to enroll in the study. * Histologically proven Prostate Carcinoma. * Undergoing total cryotherapy, focal cryotherapy, Cyberknife SBRT or radical prostatectomy for prostate cancer treatment. Exclusion Criteria: * Has previously had a radical prostatectomy for prostate cancer. * Has previously received cryotherapy for prostate cancer. * Previous treatment with chemotherapy within the past 6 months. * Previous treatment with radiation within the past 18 months. * Has evidence of metastatic disease. * Has a current or history within the past 6 months of alcohol and/or substance abuse which would impair participation in the study. * Has a major medical disorder (i.e. uncontrolled diabetes, significant hepatic, renal or hematological disorders, recent stroke or myocardial infarction), in the opinion of the urologist, is an illness or complication which is not consistent with the protocol requirements. * Is not willing to undergo the necessary follow-up for the trial period. * Has known immunologic disease, human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness.
References
Publications (0)
Data not yet available
No reference posted for this study.